Winrevair (sotatercept-csrk) - BMS, Merck (MSD)
Use of sotatercept in an adolescent patient with idiopathic pulmonary arterial hypertension. (PubMed, J Cardiol Cases) - Oct 18, 2026 - "Sotatercept may be considered as an additional therapy for pediatric patients with idiopathic pulmonary arterial hypertension. Sotatercept treatment in children with idiopathic pulmonary arterial hypertension should be evaluated further." 
Journal • Cardiovascular • Heart Failure • Hypertension • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
http://www.ncbi.nlm.nih.gov/pubmed/42889929
 
Kiyohiro Takigiku; Kohei Kurosaki; Kohta Takei; Tomoyasu Yuki; Yohei Akazawa
 
Oct 18, 2026
 
Prev Next